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Cellular/Molecular
Intracellular mGluR5 CanMediate Synaptic Plasticity in the
Hippocampus
Carolyn A. Purgert,1 Yukitoshi Izumi,2 Yuh-Jiin I. Jong,1 Vikas Kumar,1 Charles F. Zorumski,1,2 and Karen L. O’Malley1
1Department of Anatomy and Neurobiology, Washington University School of Medicine, St. Louis, Missouri 63110, and 2Department of Psychiatry and
Taylor Family Institute for Innovative Psychiatric Research, Washington University School of Medicine, St. Louis, Missouri 63110
Metabotropic glutamate receptor 5 (mGluR5) is widely expressed throughout the CNS and participates in regulating neuronal function
and synaptic transmission. Recent work in the striatum led to the groundbreaking discovery that intracellularmGluR5 activation drives
unique signalingpathways, includingupregulationofERK1/2, Elk-1 (Jonget al., 2009) andArc (Kumaret al., 2012). Todeterminewhether
mGluR5 signals from intracellular membranes of other cell types, such as excitatory pyramidal neurons in the hippocampus, we used
dissociated rat CA1 hippocampal cultures and slice preparations to localize and characterize endogenous receptors. As in the striatum,
CA1 neurons exhibited an abundance of mGluR5 both on the cell surface and intracellular membranes, including the endoplasmic
reticulum and the nucleus where it colocalized with the sodium-dependent excitatory amino acid transporter, EAAT3. Inhibition of
EAAT3 or sodium-free buffer conditions prevented accumulations of radiolabeled agonist. Using a pharmacological approach to isolate
different pools of mGluR5, both intracellular and cell surface receptors induced oscillatory Ca2 responses in dissociated CA1 neurons;
however, only intracellular mGluR5 activation triggered sustained high amplitude Ca2 rises in dendrites. Consistent with the notion
thatmGluR5can signal from intracellularmembranes, uncagingglutamateonaCA1dendrite led to a local Ca2 rise, even in thepresence
of ionotropic and cell surface metabotropic receptor inhibitors. Finally, activation of intracellular mGluR5 alone mediated both electri-
cally induced and chemically induced long-term depression, but not long-term potentiation, in acute hippocampal slices. These data
suggest a physiologically relevant and important role for intracellular mGluR5 in hippocampal synaptic plasticity.
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Introduction
G-protein-coupled receptors (GPCRs) are thought of as sim-
ple on–off switches in which extracellular ligands activate cell
surface receptors, resulting in G-protein activation and second
messenger induction. The on–off switch has now given way to
multifaceted, higher-order structures of homomers or hetero-
mers within which allosteric mechanisms can alter ligand bind-
ing,G-protein coupling, receptor internalization, trafficking, and
G-protein-independent signaling (Denis et al., 2012; Reiter et al.,
2012). With the discovery that GPCRs can trigger signaling cas-
cades from intracellular membranes (O’Malley et al., 2003; Jong
et al., 2005, 2009; Kumar et al., 2008; Bkaily et al., 2012; He-
wavitharana and Wedegaertner, 2012), referred to here as “loca-
tion bias,” GPCR functionality has become even more complex.
The metabotropic glutamate receptor 5 (mGluR5) exempli-
fies this more complex view of GPCR signaling. Not only can
mGluR5 dimerize with itself (Romano et al., 1996) and other
GPCRs (Hubert et al., 2001), it can be regulated by both positive
and negative allosteric modulators that can potentiate or inhibit
the endogenous ligand, glutamate, respectively. mGluR5 also ex-
hibits pronounced location bias in that 60–90% of mGluR5 is
associated with intracellular membranes (Hubert et al., 2001;
Lo´pez-Bendito et al., 2002; O’Malley et al., 2003). In the striatum,
previous studies from this laboratory show that endogenous
intracellular mGluR5 is functional, that it is activated by its
neurotransmitter entering neurons via sodium or chloride-
dependent transporters/exchangers (Jong et al., 2005; Kumar et
al., 2008), and that intracellular mGluR5 specifically triggers a
cascade of molecular events starting with phosphorylation of
ERK1/2 and Elk-1 (Jong et al., 2009), followed by increased ex-
pression of synaptic plasticity genes c-fos, egr-1, and Arc (Kumar
et al., 2012). Thus, activation of intracellular mGluR5 initiates a
cascade of events underlying synaptic plasticity.
Given that mGluR5 is involved in many disorders, including
fragile X syndrome/autism spectrum disorder, schizophrenia,
anxiety, addiction, levodopa-induced dyskinesias, gastroesopha-
geal reflux disease, chronic pain, and epilepsy (Catania et al.,
2007; Cleva andOlive, 2011; Blandini andArmentero, 2012; Gray
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et al., 2012), drugs that modulate its function may be extremely
useful in treating these disorders. Because it might be possible to
target drugs from one pool of receptors to another, it is critical to
understand how mGluR5 signals from both the cell surface as
well as intracellular locales. Although geneticmanipulations have
failed to cleanly isolate mGluR5 from one membrane versus
another (unpublished results), pharmacological isolation is
achieved via specific impermeable, nontransported drugs, in-
cluding the antagonist LY53 and the agonist DHPG, as well as
transported or permeable drugs, such as the agonists, Quis and
CHPG, and the antagonist, MPEP (Jong et al., 2005, 2009). Here
we show, for the first time, that intracellular mGluR5 plays a
critical role in a specific form of hippocampal synaptic plasticity.
Materials andMethods
Hippocampal cell culture. Primary hippocampal cultures were prepared
and maintained as described previously with some modifications (Jong
et al., 2005). Briefly, coverslips placed in 12-well plates were coated with
poly-D-lysine for 3–16 h and then washed three times with sterile water.
After drying, the coverslips were coated with 80 l of Neurobasal A
(Invitrogen) and prewarmed at 37°C. Dissociated hippocampal cultures
were prepared using postnatal day 1 (P1) or P2 rat pups. After decapita-
tion, brains were immediately removed and placed in cold sterile PBS.
Hippocampi were carefully removed under a dissecting microscope, and
the CA1 region was enriched by removing the dentate gyrus and CA3
regions along the inner curve of the hippocampal structure. The CA1-
enriched hippocampi were diced into 1mmpieces and incubated at 37°C
5%CO2/95%O2 for 15min in a papain solution consisting of 0.2 mg/ml
BSA, 1 mg/ml papain, and 1 mg/ml DNaseI in Neurobasal A supple-
mentedwith glutamine, B-27, and penicillin/streptomycin (NBA). The
solution was mixed every 5min during incubation. After incubation, the
supernatant was removed and the tissue was washed twice with 3 ml of
warm NBA. After removing the supernatant again, 5 ml of NBA was
used to triturate the tissue 5 times through a 5 ml pipette and then 8
times through a 200 l pipette tip. Cells were pelleted by centrifuging at
700 rpm for 5–10 min. The supernatant was removed, and the cells were
resuspended in 1 ml of NBA and counted on a hemocytometer using
Trypan blue to assess cell death. The cells were plated at a density of
40,000 cells/10 mm coverslip. Cells were allowed to adhere for 1 h, and
then 1.5 ml of NBA was added to each well. Cells were fed on DIV4–6
and on DIV11–12 by removing half of the media and replacing it with
fresh NBA.
Immunocytochemistry.Hippocampal cultures were fixed, blocked, and
incubated as described previously (Jong et al., 2005). Primary antibodies
include rabbit polyclonal anti-mGluR5 (Millipore, 1:150), mouse GFAP
(Cell Signaling Technology, 1:300), mouse monoclonal anti-laminB2
(Invitrogen, 1:100), and mouse monoclonal anti-EAAT3 (Millipore,
1:500). Secondary antibodies include goat anti-rabbit or anti-mouse Cy3
(Jackson ImmunoResearch Laboratories, 1:300), and goat anti-rabbit or
mouse Alexa-488 (Invitrogen, 1:300).
Subcellular fractionation. Subcellular fractionation was performed as
described previously (O’Malley et al., 2003; Jong et al., 2007). Specifically,
postnatal days 1, 5, 10, 15, and adult rat hippocampi were dissected and
minced on ice with a razor blade followed by resuspension in 20 volumes
of hypotonic buffer A containing 2.0 mM MgCl2, 25 mM KCl, 10 mM
HEPES, pH 7.5, and protease inhibitors (Complete Tablets; Roche Ap-
plied Science). Cells swelled for 10 min on ice followed by homogeniza-
tion using 15 strokes with a “B” pestle in a Wheaton glass homogenizer.
The homogenate was filtered through 3 layers of sterile gauze, centri-
fuged at 1000 g for 10 min, and the nuclear pellet was resuspended in
3 ml of buffer N (0.25 M sucrose in buffer A). Resuspended nuclei were
layered over 2 ml of 1.1 M sucrose in buffer A and then recentrifuged at
1000 g. After repeating the previous step twice, the final nuclear pellet
comprised the nuclear fraction, whereas the supernatant from the first
pellet was concurrently further fractionated by centrifugation at
35,000  g for 40 min. This second supernatant represented soluble,
cytoplasmic proteins, whereas the high-speed pellet contained plasma
membrane proteins. The nuclear and plasma membrane fractions were
suspended in buffer (150mMNaCl, 1mM EDTA, 0.1% SDS, 1%Nonidet
P-40, 0.5% sodium deoxycholate, 50 mM Tris-HCl pH 7.5, and protease
inhibitors) and subjected to SDS-PAGE (see below). Nuclei from P1-P5
hippocampi were also isolated using subcellular fractionation, fixed to
glass coverslips, and immunostained as described previously (Jong et al.,
2005).
Western blot analysis. Protein sample concentrations were assessed
with the Bradford assay (Bio-Rad). Samples were separated via SDS-
PAGE, blotted, and probedwith antibodies as described previously (Jong
et al., 2007). Primary antibodies include rabbit polyclonal anti-mGluR5
(Millipore, 1:750), monoclonal anti-Lamin B2 (Invitrogen, 1:2000),
polyclonal anti-pan-cadherin (Cell Signaling Technology, 1:2000), and
monoclonal anti--actin (Sigma, 1:1000). Secondary antibodies in-
cluded HRP conjugated with goat anti-rabbit IgG (Cell Signaling Tech-
nology, 1:2000) or anti-mouse IgG (Sigma, 1:2000). Signal was detected
using enhanced chemiluminescence (GEHealthcare), and densitometric
analyses of mGluR5 proteins were performed by using the Storm 860
Imager (GE Healthcare) or ChemiDoc MP System (Bio-Rad) with asso-
ciated software.
Uptake experiments. 3H-Labeled agonist uptake experiments were
performed using radiolabeled (L)-()--amino-3,5-dioxo-1,2,4-oxad-
iazolidine-2-propanoic acid (quisqualate; abbreviated Quis) (22.0 Ci/
mmol) obtained from PerkinElmer and radiolabeled L-glutamate (43.0
Ci/mmol) obtained fromGEHealthcare. Experiments were completed
as described previously (Jong et al., 2005). Specifically, unlabeled
drug was added to radiolabeled agonists (3.25 Ci/ml [ 3H]Quis or
43.08 Ci/ml L-[ 3H]glutamate) to achieve a total Quis or glutamate
concentration of 1 M. Primary hippocampal cultures were prepared
using PDL-coated 48-well plates with a density of 40,000 cells/well. Cells
were washed three times in the appropriate buffer (total buffer, contain-
ingNa andCl: 137mMNaCl, 5.1mMKCl, 0.77mMKH2PO4, 0.71mM
MgSO4.7H2O, 1.1mMCaCl2, 10mM D-glucose, 10mMHEPES; chloride-
free buffer: 130 mM Na gluconate, 5 mM K gluconate, 0.77 mM KH2PO4,
0.71 mM MgSO4.7H2O, 1.1 mM Ca gluconate, 10 mM D-glucose, 10 mM
HEPES; sodium-free buffer: 137.5 mM choline Cl, 5.36mMKCl, 0.77mM
MgSO4.7H2O, 1.1mMCaCl2) and then incubated at 37°C in the presence
or absence of various competitors/inhibitors for 15 min before adding
labeled agonist. Drugs included (S)-3,5-dihydroxyphenylglycine
(DHPG), (RS)-2-chloro-5-hydroxyphenylglycine (CHPG), L-cystine,
and DL-threo--benzyloxyaspartic acid (TBOA), all from Tocris Biosci-
ence. Uptake was terminated after 15 min, and samples were rapidly
rinsed three times with ice-cold PBS. Cells were solubilized in 150 l of
1% Triton X-100/PBS and then analyzed by liquid scintillation. Statisti-
cal significance was assessed using two-tailed, unpaired sample t tests
with Bonferroni corrections for multiple testing.
Ca2 imaging. Ca 2 imaging was performed using DIV14–18 hip-
pocampal cultures loaded with Oregon Green BAPTA-AM as de-
scribed previously (Jong et al., 2009). Images were analyzed using
MetaMorph software as described previously (Jong et al., 2009).
Agonists DHPG, CHPG, and Quis and inhibitors ()-4-
(4-aminophenyl)-1,2-dihydro-1-methyl-2-propylcarbamoyl-6,
7-methylene-dioxyphthalazine (SYM2206), 7-(hydroxyimino)cyclo-
propa[b]chromen-1a-carboxylate ethyl ester (CPCCOEt), and MPEP
were obtained from Tocris Bioscience. Impermeable, nontransported
antagonist 3-[(1S)-1-amino-1-carboxy-2-(9H-thioxanthen-9-yl)ethyl]
cyclobutane-1-carboxylic acid (LY393053; abbreviated LY53) was ob-
tained from Eli Lilly.
Caged glutamate experiments. DIV11–15 hippocampal cultures were
loaded with Oregon Green BAPTA-AM as described previously (Jong et
al., 2005). Cells were kept at 37°C and imaged on an Olympus FV1000
confocal microscope. Where indicated, the following inhibitors were
used at the indicated concentration: D-([minua])-2-amino-5-phospho-
nopentanoic acid (APV, NMDA receptor antagonist, 100 M, Tocris
Bioscience); 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX, AMPA re-
ceptor antagonist, 20 M, Tocris Bioscience); (2S)-2-amino-2-[(1S,2S)-
2-carboxycycloprop-1-yl]-3-(xanth-9-yl) propanoic acid (LY341495,
Group 2/3 mGluR antagonist, 100 nM, Tocris Bioscience); CPCCOEt
(mGluR1 antagonist, 20M), and LY53 (nontransportedmGluR5 antag-
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onist, 20 M). 4-Methoxy-7-nitroindolinyl-caged-L-glutamate (MNI-
glu, Tocris Bioscience) was added at a concentration of 500 M.
Experiments were performed by applying a 405 nm laser for 300 ms to
small regions of interest (ROI) on neurites after waiting for 30 s to estab-
lish baseline Ca2 levels. Ca2 responses in the ROI and control areas
were analyzed using MetaMorph software.
Electrophysiology. Hippocampal slices were prepared from P 28–32
albino rats using standard methods (Izumi and Zorumski, 2012). Rats
were anesthetized with isoflurane and decapitated. Dissected hip-
pocampi were placed in ice-cold ACSF containing the following (inmM):
124 NaCl, 5 KCl, 2 MgSO4, 2 CaCl2, 1.25 NaH2PO4, 22 NaHCO3, 10
glucose, bubbled with 95% O2-5% CO2 at 46°C, and cut into 450 m
slices using a rotary slicer. Acutely prepared slices were placed in an
incubation chamber containing gassed ACSF for at least 1 h at 30°C
before further experimentation. Based on numerous prior experiments,
we have found this approach to provide reliable data for synaptic plas-
ticity experiments.
At the time of study, hippocampal slices were transferred individually
to a submersion-recording chamber. Experiments were done at 30°C
with continuous ACSF perfusion at 2 ml/min. Extracellular recordings
were obtained from the apical dendritic layer (stratum radiatum) of the
CA1 region for analysis of EPSPs using electrodes filled with 2 M NaCl
(5–10 M resistance). EPSPs were evoked with 0.1 ms constant current
pulses through a bipolar stimulating electrode in the Schaffer collateral
pathway. A control input–output curve was obtained to determine stim-
ulus intensities for subsequent studies. Responses were monitored by
applying single stimuli to the Schaffer collateral pathway every 1min or 5
min at half-maximal intensity. After establishing a stable baseline for at
least 10 min, long-term depression (LTD) was induced by applying a 1
Hz stimulus to the Schaffer collateral pathway for 15 min. Long-term
potentiation (LTP)was induced by a single 100Hz 1 s tetanus using the
same intensity stimulus. Input–output curves were repeated 60min after
tetanic stimulation. All chemicals were purchased from Sigma or Tocris
Bioscience.
Data were collected and analyzed using PClamp software (Molecular
Devices). Data in the text are expressed asmean SEM60min following
low-frequency stimulation (LFS) or high-frequency stimulation (HFS),
and are normalized with respect to initial baseline recordings (taken as
100%). A two-tailed Student’s t test was used for comparisons between
groups. In cases of non-normally distributed data, the nonparametric
Mann–Whitney Rank Sum Test was used. Statistical comparisons were
based on input–output curves at baseline and 60min after tetanic or 1Hz
stimulation, with p  0.05 considered significant and were done using
commercial software (SigmaStat, Systat Software).
Results
mGluR5 is expressed on intracellular membranes in the
hippocampus where it can be activated via sodium-dependent
transport of Quis or glutamate
CA1-enriched hippocampal cultures expressed mGluR5 on the
cell surface, along dendrites, and within the cell body, where
dense staining around the nucleus colocalized with Lamin B2, a
nuclear envelope marker (Fig. 1A,B). No detectable mGluR5
staining was seen on cocultured astrocytes, marked with GFAP
(Fig. 1A). As in the striatum (Jong et al., 2005), antibodies di-
rected against EAAT3 revealed that, in hippocampal neurons,
EAAT3 is highly expressed on cell bodies and processes as well as
intracellularly (Fig. 1B, middle, right panels). Acutely isolated
hippocampal nuclei also exhibitedmGluR5 staining, which colo-
calized with Lamin B2 (Fig. 1C). Subcellular fractionation of hip-
pocampal tissue collected between newborn (P1) and adult ages
revealed strong mGluR5 staining in both nuclear and plasma
membrane fractions as delineated by the membrane specific
markers, Lamin B2 and pan-cadherin (Fig. 1D–G). Levels of nu-
clear receptors in P5 through adult samples were increased over
P1 levels, peaking at P10 and P15 (Fig. 1E,G), similar to previous
findings in the striatum (Jong et al., 2005).
Todirectly testwhether sodiumorchloride-dependentprocesses
were involved in Quis or glutamate uptake in CA1 cells, cultures
were treatedwith radiolabeled ligand in the presence and absence of
transport or exchange inhibitors. Glutamate blocked70%ofQuis
transport, whereasDHPGdidnot competewith the uptake of either
radiolabeled agonist (Fig. 1H,I). In contrast to the striatum, no role
for the cystine glutamate exchanger (xCT)was seen inCA1 cultures;
rather, a sodium-dependent,TBOA-inhibitedprocess accounted for
80–90% of 3H-glutamate uptake and 50% of 3H-Quis uptake
(Fig. 1H,I). The process responsible for the remaining Quis uptake
is unclear at present. The vesicular glutamate transporter (VGLUT)
inhibitor Evans blue did not affect Quis uptake, nor did addition of
succinate (data not shown), indicating that neither VGLUTs nor
succinate transporters are involved in Quis transport. Therefore, in
both striatal (Jong et al., 2005) and CA1 cultures, EAAT-mediated
activity is primarily responsible for intracellular glutamate uptake.
Also in agreement with data from the striatum (Jong et al.,
2009), glutamate binding assays showed no significant differ-
ences in receptor binding between DHPG and Quis to either
plasma membrane or intracellular membrane sources (DH-
PGplasma membrane IC50 	 0.92  0.29 M; DHPGnuclei IC50 	
2.96  1.00 M vs Quisplasma membrane IC50 	 0.76  0.12 M;
Quisnuclei IC50 	 3.08  0.89 M;
p	 0.0674 for DHPGplasma membrane vs DHPGnuclei; p	 0.0671
forQuisplasma membrane vsQuisnuclei;p	0.310 forDHPGplasma membrane
vs Quisplasma membrane; p	 0.311 for DHPGnuclei vs Quisnuclei). Thus,
differences in binding properties betweenDHPG andQuis cannot ac-
count for differences in activation of cell surface versus intracellular
mGluR5.
Differential Ca2 responses are seen in dendrites after
intracellular, but not cell surface, mGluR5 activation
In CA1-enriched cultures, the impermeable, nontransported ago-
nist, DHPG, induced pronounced cytoplasmic Ca2 oscillations,
which could be blocked by the permeable antagonist, MPEP (Fig.
2A). Akin to striatal neurons (Jong et al., 2005), the impermeable/
nontransported antagonist LY53, by itself, did not induce intracel-
lular Ca2 changes (Fig. 2B); instead, it completely blockedDHPG-
mediated Ca2 responses (Fig. 2B). These data confirm and
extend our finding that DHPG selectively activates plasma
membrane receptors that are susceptible to inhibition by the
LY53 antagonist. In contrast, Quis induced cytoplasmic Ca2
oscillations, even in the presence of LY53 (Fig. 2B). These oscil-
lationswere inhibitedwhenMPEPwas added (Fig. 2B). Similarly,
the mGluR5-specific agonist CHPG triggered Ca2 oscillations,
even in the presence of LY53, which were similarly blocked by
MPEP (Fig. 2C). Oscillatory Ca2 responses were also observed
in dendrites after activation of cell surface mGluR5 (Fig. 2D) or
intracellular mGluR5 (Fig. 2E,F). Dendrites, identified based on
morphological criteria and MAP2 staining (data not shown),
showed no agonist-mediated differences in oscillation frequency
versus CA1 somal responses (Fig. 2G). Similarly, no agonist-
mediated differences in amplitude were measured in CA1 soma,
whereas significantly increased amplitudes attributable to intra-
cellular mGluR5 were observed in dendrites (Fig. 2H). Increased
amplitude was associated with sustained Ca2 responses (Fig.
2E,F), such as those commonly seen in striatal neurons (Jong et
al., 2005). Forty to 80% of CA1 dendrites exhibited high-
amplitude, sustained Ca2 responses measured 50 m from the
cell body after intracellular mGluR5 activation (Fig. 2I). These
data support the concept that mGluR5 can couple to unique
effector mechanisms depending upon the following: (1) the cell
type in which it is expressed (inhibitory medium spiny neurons
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in striatum vs excitatory pyramidal CA1
neurons); or (2) whether the receptor is
localized to the dendrite or the soma.
Intracellular mGluR5 canmediate local
Ca2 changes in dendrites
Although we have primarily characterized
intracellular mGluR5 expressed on nuclear
membranes in the striatum, ultrastructure
studies have also shown large numbers of
mGluR5 gold particles on endoplasmic re-
ticulum (ER) membranes (O’Malley et al.,
2003). Moreover, many earlier ultrastruc-
tural studies of various brain regions from
the rat, mouse, and monkey have shown
large amounts of intracellular mGluR5 in
dendrites (e.g., Mitrano and Smith, 2007)
(see Fig. 4D), at the edge of asymmetric
postsynaptic specializations and extrasyn-
aptically along the plasma membrane (Lu-
jan et al., 1996; Hanson and Smith, 1999;
Hubert et al., 2001; Kuwajima et al., 2004;
Mitrano et al., 2008, 2010). To address the
question as to whether mGluR5 expressed
on dendritic ER or endosomal membranes
can mediate local Ca2 rises, intracellular
receptors were pharmacologically isolated
by blocking cell surface mGluR5 with LY53
as well as other potential glutamate targets,
suchas the ionotropic receptors (NMDARs,
AMPARs, kainate receptors), mGluR1, and
Groups 2 and 3 mGluRs. In addition to in-
hibitors, extracellular buffer also contained
MNI-glutamate, which was uncaged using
laser-induced photolysis onto dendrites at
least 20maway fromthe cell body (Fig. 3).
Only the region of the dendrite juxtaposed
to the uncaging spot exhibited a change in
fluorescence whereas proximal regions re-
vealed no such fluorescent changes (Fig. 3),
and this Ca2 response was blocked in the
presence of MPEP. These data indicate that
activation of dendritic, intracellular
mGluR5 leads to in situ Ca2 changes with
neither input to nor output from the cell
soma.
mGluR5 knock-out mice do not exhibit
mGluR5-dependent synaptic plasticity
WeusedmGluR5-deficient animals to de-
termine the specificity of agonist-
mediated Ca2 responses in hippocampalFigure 1. mGluR5 present on intracellular hippocampal membranes can be activated by EAAT3-dependent transport of gluta-
mate or Quis. A, Immunostaining for mGluR5 (green, left), GFAP (red, middle), and an overlay image showing that mGluR5 is not
expressed in GFAP-positive cells (astrocytes) in DIV14 rat CA1-enriched hippocampal cultures.B, Left, Confocal images ofmGluR5-
positive hippocampal neuron costained for the nuclear membrane marker Lamin B2 showing the receptor present in the cyto-
plasm, neurites, and as a densely stained ring corresponding to the nuclear membrane. Middle, CA1-enriched hippocampal
cultures also express EAAT3, which is coexpressedwithmGluR5 (right). C, Isolated adult rat hippocampal nuclei coexpressmGluR5
and Lamin B2.D, Subcellular fractionation of adult mouse hippocampi shows thatmGluR5 can be detected in fractions containing
either plasma (PM)or nuclearmembranes (NUC). A total of 30gof protein fromeach fractionwas separatedon reducing SDSgels
and transferred to PVDFmembranes. The sameblotwas cut andprobedwith antibodies againstmGluR5, the inner nuclearmarker,
Lamin B2, and the plasma membrane marker, Pan-cadherin. E, Top, P1, P5, P10, P15, and adult rat isolated nuclei were electro-
phoretically separated as inD and immunoblotted in an identical fashion. F, Quantification ofmGluR5 expression inmouse PMand
nuclear fractions shown in D; n	 3. G, Quantification of rat hippocampal mGluR5 expression across different ages as shown in E.
*p 0.05, compared with P1 levels. #p 0.05. n	 3. H, [ 3H]Quis uptake
4
in hippocampal cultures in the presence of 100M glutamate,
100M DHPG, 50–100M TBOA, or buffer conditions modi-
fied as indicated. Bars indicate experimental mean  SE.
*p 0.01, **p 0.001 (n	 15 glu; n	 6 DHPG; n	 9
Na-free and Cl-free conditions; n	 15 TBOA). I, [ 3H]Gluta-
mate uptake in hippocampal cultures in the presence of 100
M DHPG, 20 M LY53, 400 M L-cystine (L-Cys), 100 M
TBOA, or buffer conditionsmodified as indicated. Bars indicate
the mean of 3 experiments SE. *p 0.01.
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neurons and mGluR5-mediated LTP and LTD. Hippocampal
cultures prepared fromknock-outmGluR5 P1mouse pups failed
to display oscillatory Ca2 responses after application of Quis,
whereas wild-type littermate animals displayed oscillations sim-
ilar to those seen in rat hippocampal cultures (Fig. 4A,B). In
addition, electrical LTP and LTD paradigms failed to induce per-
sistent synaptic strength changes in P30 hippocampal slice prep-
arations from mGluR5 knock-out mice versus wild-type
Figure 2. Both cell surface and intracellular mGluR5 produce Ca 2 oscillations in cell bodies, whereas only intracellular receptors induce sustained Ca 2 responses in dendrites. A–F,
Representative traces of Ca 2 responses in dissociated CA1neurons represented as the fractional change in fluorescence relative to the basal level. Neuronswere treatedwith the indicated agonists
and antagonists by bath application at the time indicated by the black arrows. The black bar represents pretreatment of cultures with the nontransported mGluR5 antagonist LY53. The AMPA
receptor blocker SYM2206 (20M) and the mGluR1 blocker CPCCOEt (20M) were included in all experiments. Data were acquired at 9.59 s/scan. DHPG was used at 10–100M, LY53 at 20M,
Quis at 20M, and MPEP at 1–10M. A, Cytoplasmic Ca 2 oscillations induced by 10 or 100M DHPG are inhibited by application of MPEP. B, Pretreatment with the nontransported mGluR5
antagonist LY53 blocks DHPG but not Quis-induced Ca 2 oscillations. C, The transported agonist CHPG is also able to produce Ca 2 oscillations in the presence of LY53. D–F, DHPG induces Ca 2
oscillations in dendrites50 m from the cell body (D), whereas dendritic intracellular mGluR5 (defined by Quis or CHPG treatment in the presence of LY53) produce more pronounced and
sustained Ca 2 responses (E, F). G–I, Compiled data of
F/Fo (%) for frequency of oscillations (G) in soma (blue bar) or dendrites (red bar), for amplitude (H) and for sustained responses (I) from
n 60 neurons or n 30 neurites from three independent experiments. *p 0.05, compared with baseline Ca 2 responses. #p 0.01, compared with baseline Ca 2 responses. Cells with at
least 3 oscillations of at least 25% change in fluorescence were included in calculations for oscillatory frequency.
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littermates (Fig. 4C,D). Similarly, chemical LTD induced by
CHPG was absent in mGluR5 knock-out animals (Fig. 4E). Sur-
prisingly, DHPG-LTD, a common chemical LTDmodel (Palmer
et al., 1997; Huber et al., 2001), was only partially suppressed in
mGluR5-null mice.
Intracellular mGluR5 alone canmediate LTD, but not LTP
In the striatum, activation of intracellular mGluR5 initiates a
cascade of events underlying synaptic plasticity. Because numer-
ous studies have suggested that mGluR5 is critically linked with
changes in hippocampal LTP and LTD (Izumi et al., 2000), we
tested whether intracellular mGluR5 also plays a role in these
forms of synaptic plasticity. Consistent with previous work
(Izumi et al., 2000), an HFS protocol applied to Schaffer collat-
erals in hippocampal slices induced a persistent 25–55% facilita-
tion 1 h after stimulation (Fig. 5A). The nontransported
antagonist LY53 blocked HFS-LTP, indicating that cell surface
mGluR5 is critical in eliciting this form of LTP (Fig. 5A). MPEP,
an antagonist that acts at both cell surface and intracellular
mGluR5, also blocked HFS-LTP.
Synaptically induced mGluR-LTD can be evoked in hip-
pocampal slices using LFS (Izumi et al., 2000) or by chemical
agonists, such as Quis (Nicoletti et al., 2011), DHPG (Palmer et
al., 1997; Huber et al., 2001), or CHPG (Palmer et al., 1997;
Neyman and Manahan-Vaughan, 2008; Izumi and Zorumski,
2012). LFS normally induces 20–30% depression 1 h after stim-
ulation. As observed by other investigators, MPEP application
blocked LFS-LTD (Neyman and Manahan-Vaughan, 2008).
However, in contrast toHFS-LTP, LY53was unable to block LTD
induction (Fig. 5B), indicating that intracellular mGluR5 was
sufficient for this process. In terms of chemical LTD, application
of LY53 was able to block DHPG-LTD (Fig. 5C), but not CHPG-
LTD (Fig. 5D) or Quis-LTD (Fig. 5E), indicating that activation
of intracellular mGluR5 alone was sufficient to induce LTD and
that cell surface mGluR5 was not required. As a control, MPEP
was able to block both CHPG-LTD and Quis-LTD (Fig. 5D,E),
indicating that these forms of LTD are mediated by mGluR5.
Finally, incubation with the translation inhibitor anisomycin
blocked CHPG-LTD (Fig. 5F), which agrees with previous stud-
ies thatmGluR5-LTD is protein translation-dependent (Huber et
al., 2000).
Discussion
Because mGluR5 is critically linked with fragile X syndrome, au-
tism spectrum disorder, and many other disorders (Krueger and
Bear, 2011), it is a key target for drug discovery. Surprisingly, no
studies to date have focused on intracellular mGluR5 as a con-
tributing factor to these disorders. The present findings show
that, as in striatal neurons, intracellular mGluR5 is both present
and functional in hippocampal neurons, where it can cause den-
dritic Ca2 rises that differ in amplitude from cell surface recep-
tor activation. Using genetic, physiological, and pharmacological
techniques, these studies also show that intracellularmGluR5 can
mediate protein-synthesis-dependent LTD, whereas cell surface
mGluR5 is involved in both LTD and LTP. Thus, there may be
large gaps in our understanding of mGluR5-LTD because of the
contributions of intracellular mGluR5 signaling. Studies target-
ing drugs to cell surface versus intracellular receptors might lead
to new therapeutic tools for fragile X syndrome/autism spectrum
disorder, and levodopa-induced dyskinesias, gastroesophageal
reflux disease, schizophrenia, and pain.
Although we would like to target mGluR5 to one membrane
versus another, unequivocal targeting motifs have yet to be de-
fined. Pharmacological isolation can be achieved, however, using
a combination of impermeable, nontransported drugs together
with permeable or transported ones. Drug permeability can be
gauged using PubChem’s lipophilicity values (LogP) in which a
LogP value2 is considered to be readily membrane permeable
(Lester et al., 2012). Only MPEP has a LogP2 (3.3), which is in
agreement with its ability to block all mGluR5 responses on and
Figure 3. Regionally selective uncaging of glutamate in the presence of cell surface inhibitors activates intracellular mGluR5 in dendrites. A, Selective uncaging of MNI-glu in an ROI allows it to
be taken up into the dendrite and subsequently the ER via EAAT3 transporters where it activatesmGluR5. This leads to signaling via IP3 to release Ca
2 from the lumen of the ER.B, C, MNI-glu was
uncaged on aneurite of a CA1pyramidal cell at the red ROI in the presence of LY53 (20M), theNMDA receptor blocker APV (100M), the AMPA/kainate receptor blocker CNQX (20M), themGluR1
blocker CPCCOEt (20M), and theGroup 2mGluR antagonist LY341495 (100 nM). Uncaged glutamate generated a Ca 2 rise at the red ROI,whereas no Ca 2 changes are seen proximal (greenROI),
distal (lavender ROI), or in a different neurite in the same field (blue ROI) (n	 5).
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within the cell (e.g., Fig. 2). LogP values for glutamate (2.7),
DHPG (2.4), CHPG (1.4), LY53 (0.6), and Quis (3.9) are
consistent with the notion that they aremembrane impermeable.
Thus, for any of these compounds to get into the cell, there must
be an active transport/exchange process. With radiolabeled ana-
logs, such as exist for Quis and glutamate, it is easy to show that
both are transported into neurons via a sodium or chloride-
dependent process (Jong et al., 2005, 2009; Kumar et al., 2008)
(Fig. 1H, I).Without such a radiolabel, we have used competition
assays to show that LY53 and DHPG do not compete with radio-
labeledQuis or glutamate for cell entry, whereas CHPGdoes (Fig.
1H). Additional functional data come from nuclei themselves.
Because nuclei are composed of a double membrane and the
mGluR5 ligand binding domain is within the nuclear lumen
(O’Malley et al., 2003), only a permeable or transported drug can
activate nuclear mGluR5. DHPG cannot induce nucleoplas-
mic Ca2 changes in purified nuclei endogenously expressing
mGluR5, whereas the subsequent application of Quis to the same
organelle induces a robust response, one that is not blocked by
LY53 (Jong et al., 2009). Collectively, these data and sources pro-
vide strong evidence that DHPG and LY53 only affect cell surface
mGluR5, not intracellular receptors. In the hippocampus,
mGluR5-induced changes in synaptic plasticity (mGluR5-LTD)
have been primarily defined by DHPG (Palmer et al., 1997; Hu-
ber et al., 2001), which, as discussed above, only activates cell
surface receptors (Jong et al., 2005). Thus, DHPG-induced LTD
activates only a portion of mGluR5 responses. In addition, some
of the DHPG-induced signals might represent off-target effects.
For example, we recently reported that LTD induced by 100 M
DHPG is not blocked by MPEP, indicating that DHPG actions
Figure 4. mGluR5 knock-out animals do not display mGluR5-dependent synaptic plasticity. A, Representative traces of Ca 2 responses shown as the fractional change in fluorescence relative
to thebasal level. CA1neuronswere treatedwith20MQuis and10MMPEP, as indicatedby the arrows.Onlywild-typemGluR5neurons (black lines) displayedQuis-inducedCa 2 responses (n	
42 responding cells of 97 analyzed from 3 different animals), whereas neurons derived from mGluR5-null mice (gray line) did not respond to Quis (n	 0 responding cells of 72 analyzed from 3
different animals). B, Compiled data from mGluR5/ (black bar) and mGluR5/ neurons (gray bar). *p 0.001. C–F, Electrophysiology (n	 5 wild-type, n	 9 KO for each experiment):
HFS-LTP (100pulses at 100Hz;C), LFS-LTD (900pulses at 1Hz;D), and CHPG-LTD (E) are absent inmGluR5KOanimals,whereasDHPG-LTD (F) is only partially diminished.C,D, Insets, Representative
traces. Dashed lines indicate baseline; solid lines indicate traces in response to the indicated treatment after 60 min. Calibration: 1 mV, 5 ms.
Purgert et al. • Intracellular mGluR5 in the Hippocampus J. Neurosci., March 26, 2014 • 34(13):4589–4598 • 4595
are not completely specific (Izumi and Zorumski, 2012). Al-
though only 10 M DHPG was used here to induce chemical
LTD, even this low concentration induced partial LTD in
mGluR5 KO mice (Fig. 4F). These results confirm DHPG off-
target effects and possible compensatory changes in expression of
other receptors in mGluR5 KO mice compared with wild-type
mice or rats. In contrast, HFS, LFS, and CHPG-induced re-
sponses were completely absent in mGluR5 KO slices. In wild-
type slices, HFS or LFS activates intracellular mGluR5 via
synaptically released glutamate uptake, presumably via EAAT3
(Jong et al., 2009) (Fig. 1I). Our findings that LY53 completely
blocked HFS-induced LTP and DHPG-induced LTD, but not
LFS or CHPG-induced LTD, led us to conclude that activation of
intracellular mGluR5 is sufficient to produce LTD but not LTP.
One caveat to the latter, however, is that because a selective intra-
cellular mGluR5 inhibitor is not currently available (MPEP in-
hibits both surface and intracellular mGluR5s), the possible
involvement of intracellular mGluR5 in LTP cannot be excluded.
mGluR-LTD has been shown to be dependent on protein
translation, but not mRNA transcription (Huber et al., 2000). In
accordance with this, CHPG-LTD in our experiments was simi-
larly translation-dependent, as it was blocked by anisomycin (Fig.
5F). Because intracellular mGluR5 activation alone can drive
CHPG-LTD (Fig. 5D), this suggests that intracellular mGluR5,
like its cell surface counterpart, also induces LTD via a protein
translation-dependent mechanism.
mGluR5oscillatoryCa2 responses are thought to result from
rapid, cyclical phosphorylation via PKC, which uncouples the
receptor fromGq/11/PLC activation (Kawabata et al., 1996; Kimet
al., 2005). In addition toPKC, receptor density and levels of ago-
nist stimulation can affect Ca2 responses (Kawabata et al., 1996;
Kim et al., 2005). Thus, potential regional differences in receptor
density might explain somal oscillations versus sustained den-
dritic Ca2 patterns (Fig. 2). An alternative explanationmight be
a difference in the types of proteins that are complexed with cell
surface receptors in the soma or dendrites and/or intracellular
Figure5. Activation of intracellularmGluR5 canmediate LTD, not LTP.A, HFS induced an enhancement of dendritic EPSPs that persisted for at least 60min after stimulation. HFS-LTPwas blocked
by 10M LY53 or 10MMPEP (n	 6 control, n	 7 LY53, n	 5MPEP).B, LFS induced persistent synaptic depression that was not blocked by 10M LY53, but was blocked by 10MMPEP (n	
5 for each condition). C, DHPG (10M) induced LTD that was blocked by 10M LY53 or by 10M MPEP (n	 5 for each condition). D, CHPG (250M) also induced LTD that was not blocked by 10
M LY53 butwas blocked by 10MMPEP (n	 10 control, n	 7 LY53, n	 5MPEP). E, Application of 10M Quis (white bar) for 15min (in the presence of inhibitors to isolatemGluR5 activation:
10M CNQX, 20M CPCCOEt, 100M APV; striped bar) induced chemical LTD (open circles). The depressionwas attenuated by 10MMPEP (gray bar; triangles), but not by 10M LY53 (black bar;
closed circles) (n	 5 for each experiment). F, Translation inhibitor anisomycin (20M) blocks CHPG-LTD (n	 5). Insets, Representative traces. Dashed lines indicate baseline; solid lines indicate
traces in response to the indicated treatment after 60 min. Calibration: 1 mV, 5 ms.
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receptors in any location. The C terminus of mGluR5 interacts
with many scaffolding proteins, including homers, which link
mGluR5 on the plasma membrane to surface and intracellular
Ca 2 channels, NMDA receptors, as well as other binding
proteins, such as CAL, Norbin, calmodulin, SIAH, Tamalin,
NECAB2, CAIN, PKC, GRK2, CaMKII, and various cytoskeletal
components (Enz, 2012; Fagni, 2012). Therefore, unique func-
tional signaling entities might be found at cell surfaces or intra-
cellular membranes in somal compartments and similarly at
dendritic surface or intracellular membranes. Other possible ex-
planations for the differences in somal versus dendritic Ca2
signaling characteristics would include the embryonic age of
the cultures versus the postnatal slice preparations and the
dissociated nature of in vitro neurons versus the intact con-
nections in an ex vivo slice preparation. Determining which of
these mechanisms underlies this phenomenon will require
further experimentation.
Given that striatal cultures consist mainly of inhibitory
GABAergic medium spiny neurons whereas CA1-enriched hip-
pocampal cultures are primarily excitatory glutamatergic pyra-
midal cells, these studies extend the repertoire of intracellular
mGluR5 into a different cell type. As such, intracellular mGluR5
responses might exhibit different downstream sequelae and use
unique signaling pathways. One possible point of convergence,
however, might lie in the intracellular mGluR5-mediated activa-
tion of synaptic plasticity genes, such as activity-regulated
cytoskeletal-associated protein (Arc/Arg3.1) in the striatal cul-
ture system (Kumar et al., 2012). Interestingly, Arc upregulation
has been associated with both LTD and LTP induction in the
hippocampus (Bramham et al., 2008). Therefore, determining
whether cell surface, intracellular, or both pools of mGluR5 un-
derlies this response is important.
Whereas isolated nuclear preparations comprise a suitable
means by which to study receptors on the nuclear membrane,
other intracellular membranes are more difficult to isolate while
maintaining functionality. Although mGluR5 located on the ER
has not been physically isolated, uncaging glutamate in the pres-
ence of LY53 (Fig. 3) clearly demonstrates that mGluR5 localized
to this organelle is not just undergoing maturation and process-
ing but is also capable of sending signals. Because the ER extends
into dendritic spines (Wagner et al., 2011) and rapid translation
of synaptic proteins involved in LTD is thought to occur locally at
the synapse, it is conceivable that mGluR5 located on dendritic
spine ER is responsible for the LTD effects shown in Figure 5.
mGluR5 is highly regulated by various activity-dependent
processes, notably phosphorylation at multiple sites via multiple
kinases largely resulting in receptor internalization (Mao et al.,
2008). Although internalization is often thought of as a way to
terminate receptor signaling, the discovery that endocytosed
GPCRs can trigger a whole new battery of intracellular messen-
gers has catalyzed the search for (1) “biased ligands” that can shift
a receptor’s response from one signaling pathway to another and
(2) the underlying mechanisms associated with the novel signal-
ing pathways (Reiter et al., 2012). Interestingly, mGluR5 ’s close
homolog,mGluR1, has been reported to display ligand bias (Em-
ery et al., 2012; Kammermeier, 2012). Specifically, succinic and
glutaric acid appeared to bias mGluR1 toward -arrestin-
mediated signaling, whereas both DHPG and Quis biased
mGluR1 toward G-protein signaling in heterologous cells (Em-
ery et al., 2012). These biased ligand effects were not observed for
mGluR5 (Emery et al., 2010). Furthermore, mutations in the
-arrestin binding site on the C terminus of mGluR5 (Sorensen
and Conn, 2003) do not affect the patterns of Ca2 signaling
(unpublished data). Thus, results in both striatal neurons and
hippocampal CA1 cells reflect location bias as opposed to ligand
bias.
In conclusion, the findings presented here underscore the idea
that mGluR5 is functional on intracellular membranes as well as
on the cell surface. Although past experiments have examined
mGluR5 in heterologous cell types and striatal cultures, here we
show intracellularmGluR5 is functional in the hippocampus and
directly involved in synaptic plasticity. Further studies regarding
the signaling properties of intracellular mGluR5 could be bene-
ficial in the development of targeted therapeutics to correct the
synaptic defects present in mGluR5-related disorders.
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